# BeiGene

A Bitter Pill: Trump’s 100% Drug Tariffs and the Future of Chinese Biotech

President Trump has signed an executive order under Section 232 to impose 100% tariffs on imported patent drugs and APIs, aimed at forcing price concessions and manufacturing onshoring. While Chinese biotech firms face new challenges, many are already pivoting toward U.S.-based production to mitigate these trade risks.